A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials | Scientific Data
![PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46d1d0ae52e9c099508514ee695d109b6334231c/8-Table5-1.png "PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar")
PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar
Keeping Pace With Evolving Management Strategies in Castration-Resist…
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open ...
![PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46d1d0ae52e9c099508514ee695d109b6334231c/2-Figure1-1.png "PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar")
PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | NEJM
Safety and efficacy of apalutamide in Japanese patients with metastatic castrationâ•'sensitive prostate cancer receiving an
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary - Urology
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial | Nature Medicine
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
Criteria of Progression for Trial Eligibility By Disease Manifestation | Download Table
PDF) Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer | NEJM
Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database | Scientific Reports
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial | Journal of Clinical Oncology
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Mul
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
![PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46d1d0ae52e9c099508514ee695d109b6334231c/4-Table2-1.png "PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar")
PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
647 PHASE 1–2 STUDY OF MDV3100 IN PRE- AND POST-DOCETAXEL ADVANCED PROSTATE CANCER: LONG-TERM EFFICACY RESULTS | Journal of Urology
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors | Prostate Cancer and Prostatic Diseases
